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ABSTRACT 
Purpose: Increasing numbers of haematology cancer survivors warrants identification of the most 
effective model of survivorship care to survivors from a diverse range of haematological cancers 
with aggressive treatment regimens. This review aimed to identify models of survivorship care to 
support the needs of haematology cancer survivors. 
Methods: An integrative literature review method utilised a search of electronic databases 
(CINAHL, Medline, PsycInfo, PubMed, EMBASE, PsycArticles, Cochrane Library) for eligible 
articles (up to July 2014). Articles were included if they proposed or reported the use of a model 
of care for haematology cancer survivors. 
Results: Fourteen articles were included in this review. Eight articles proposed and described 
models of care and six reported the use of a range of survivorship models of care in haematology 
cancer survivors. No randomised controlled trials or literature reviews were found to have been 
undertaken specifically with this cohort of cancer survivors. There was variation in the models 
described and who provided the survivorship care. 
Conclusion: Due to the lack of studies evaluating the effectiveness of models of care, it is 
difficult to determine the best model of care for haematology cancer survivors. Many different 
models of care are being put into practice before robust research is conducted. Therefore well-
designed high quality pragmatic randomised controlled trials are required to inform clinical 
practice. 
 
Key Words: models of care; survivorship; haematological cancer; nurse-led; shared care; follow-
up care. 
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INTRODUCTION 
Internationally, survivorship care is recognised as a priority in the cancer care continuum. 
This has been principally guided by the Institute of Medicine (IOM) report in 2005, From 
Cancer Patient to Cancer Survivor: Lost in Transition [1]. By 2008, sixteen European countries 
had defined national cancer plans, but to date very few have survivorship services operating [2]. 
The National Coalition for Cancer Survivorship [3] defines survivorship as the experience of 
living with, through and beyond a diagnosis of cancer and includes the impact on family, friends 
and caregivers. It is recognised throughout the literature, based on the IOM essential components 
of survivorship care, that survivorship care should include the following components [4, 5]: 
 Prevention; screening and interventions for recurrence, long-term and late effects; early 
detection of new cancers; 
 Assessment, support, management and information provision of physical, psychological, 
social and spiritual needs; 
 Monitoring, information, and promotion of healthy living behaviours and disease prevention; 
 Coordination of care between providers to communicate overall health needs. 
Current conventional models of survivorship care, including routine follow-up, predominately 
focus on surveillance for recurrence and monitoring of physical side effects, rather than 
provision of supportive care, health promotion, late effects monitoring and surveillance for new 
cancers [6, 7]. With an increasing awareness that communication between health care 
professionals and patients is suboptimal and that information provided to patients and primary 
care providers at treatment completion is often inadequate [8, 9], there is a growing movement to 
redesign how survivorship follow-up care is delivered. Furthermore, cancer patients frequently 
experience multiple health problems earlier than the general population [10], suggesting a need 
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for early and ongoing, comprehensive approaches to management designed to promote and 
support patient participation in maximising recovery.  
Haematology cancer patients are underrepresented and understudied in survivorship care [11] 
despite international figures indicating an increase in five year relative survival rates [12]. The 
most common haematological cancers are leukaemias, lymphomas and multiple myelomas 
(MM) [13]. Each of these has distinctive and complex treatment regimens that commonly 
involve aggressive high dose chemotherapy agents, and/or targeted therapies, radiotherapy and 
haematopoietic stem cell transplants [14]. Unfortunately, the consequence of largely aggressive 
treatment includes long-term and late physical, practical and psychosocial effects which include: 
fear of recurrence; fertility; relationship; financial; employment and insurance issues [15-17]. A 
qualitative study on specialist-led follow-up with haematology cancer survivors reported a lack 
of preparation and support in finding information and resources with poor continuity of care as 
patients transitioned into the survivorship phase [18]. These patients therefore may require 
models of survivorship care with specific components that differ from those designed for the 
more common cancers (breast, prostate and colorectal).  
Two systematic reviews [19, 20] and a literature review [6] on survivorship models of care 
have been recently published. Sussman et al. [20] reviewed 12 randomised controlled trials 
(RCTs) and four systematic reviews. De Leeuw, Larsson [6] reviewed 21 nurse-led follow-up 
studies and Howell et al. [19] evaluated 10 practice guidelines and nine RCTs. All primary 
outcomes in the reviewed studies were related to recurrence detection and in some cases health-
related quality of life and/or patient satisfaction [6, 19, 20]. Importantly, all studies included 
cancers with similar trajectories of care (breast, prostate, colon) making generalisations to other 
complex cancers such as haematological cancers difficult. Therefore, the haematology focus of 
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this integrative literature review will add to the limited body of knowledge currently available in 
this cohort of survivors. 
This integrative literature review undertook an analysis of the literature to examine the 
following questions: 
1. What are the common attributes of survivorship models of care developed generally for 
cancer patients and specifically for haematology cancer patients?  
a. What resources (human, financial, tools, care plans) are required to support these 
models of care?  
b. What are the potential benefits and shortfalls of these models of care?  
c. What outcome measures have been used to evaluate these models of care and what 
are the findings? 
 
METHOD 
The integrative literature review method was chosen as the theoretical framework to 
guide this review. It is structured according to five stages: problem formulation; literature search; 
data evaluation; data analysis and presentation. This allows for an in-depth evaluation of the 
issues encompassing the empirical, theoretical and clinical approaches within a structured 
systematic methodology [21].  
 
PROBLEM FORMULATION 
To date, the term ‘Model of Care’ (MOC) has not been well defined in published 
literature. In this review, MOC, as defined by the Robert Wood Johnson Foundation [22], is a 
conceptual outline of how to plan all current and future facility and clinical services to guide and 
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direct a patient’s experience within a health care system. Essential elements of any MOC 
include: a clear identification of health professionals responsible for planning and coordination 
of care; care delivery setting [20]; promotion of health maintenance; effective illness 
interventions; and establishing and evaluating expected clinical outcomes [23]. The medical 
specialist has traditionally led haematology cancer care follow-up, however other models of 
cancer survivorship follow-up are now emerging [24]. Therefore the focus of this integrative 
literature review was to identify models of care used by health care providers to ensure quality 
survivorship follow-up for haematology cancer survivors.  
  
LITERATURE SEARCH 
The primary search utilised the following electronic databases: Cumulative Index to 
Nursing and Allied Health Literature (CINAHL); Medline; PsycInfo; PubMed; EMBASE; 
PsycArticles and Cochrane Library from earliest records to July 2014. Combinations of the 
following search terms were used: (model of care or follow-up or nurse-led or shared care or 
primary care provider-led or General Practitioner-led or oncology-led or end of treatment or post 
treatment) and (survivorship or cancer survivor or survivorship care) and (cancer or neoplasm or 
oncology) and (haematology or leukaemia or lymphoma or multiple myeloma). A hand search of 
the reference lists from full text articles was correspondingly employed. Searches were restricted 
to the English language, humans and adults. Inclusion criteria used were: clinician experiences of 
MOC for the post treatment phase of haematological cancer; articles that reported on models of 
care; and articles that reported on the structure of survivorship services. Exclusion criteria were: 
studies with less than a 50% haematology cancer patient / haematologist cohort; studies that 
reported MOC for patients who received curative surgery only (i.e. no chemotherapy and/or 
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radiotherapy treatment); studies reporting MOC from child, adolescent or adult survivors of a 
childhood cancer; non-cancer MOC studies; MOC studies that lacked provider of survivorship 
care information; and opinion papers, letters, editorials, commentaries, conference abstracts, 
conference proceedings or case studies.  
 
DATA EVALUATION STAGE 
Abstract titles were reviewed by one author [KT] to assess eligibility. A summary of the 
selection process [25] is provided in Figure 1. The initial search yielded 2907 abstracts. 
Following removal of duplicate articles and screening using the exclusion and inclusion criteria, 
61 full-text articles were retrieved. Of these, 14 articles met the inclusion criteria and were 
included in this review. Methodological characteristics documented included: authors; 
publication year; country; study design; model; provider; disease; years post treatment; sample 
size and response rate; resources required; potential benefits; potential deficits; outcome 
measures; results and level of evidence developed by Melynyk, Fineout-Overholt [26] shown in 
Table 1. Due to variations in study population and methodologies used, meta-analysis was not 
possible.  
 
RESULTS 
Study characteristics  
No systematic reviews of haematology cancer survivorship models of care were found. In 
total, 14 articles were included in this review. Eight articles described and proposed different 
models of survivorship care [27, 28, 1, 5, 29, 30, 9, 7] (Table 2). An additional six articles 
reported the use of a range of models of care for haematology cancer survivors: two reported 
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nurse-led studies [31, 32] and four referred to physician-led studies [33, 8, 34, 35] (Table 3). The 
included articles reported views from Australia (n=1), United States of America (USA) (n=10) 
and United Kingdom (UK) (n=3), shown in Table 3. The eight articles that described and 
proposed various models of survivorship care were categorised into three main settings: hospital-
based; primary care-based and shared care and included models, providers, and characteristics. 
The results are shown in Table 2. These included articles used multiple terms to describe 
clinicians. For clarity, the following terms have been used: primary care provider (PCP) to 
denote community-based general practitioners (GP) or family physicians; specialist to represent 
the main hospital consultant oncologist (medical, radiation, surgical) or haematologist; and nurse 
which includes nurse specialist, nurse practitioner (NP) or nurse coordinator. 
Of the six studies that reported the use of specific models of survivorship care, four were 
quantitative and two were qualitative studies. Studies reflected moderate (IV) to low (VI) levels 
of evidence.   
 
DATA ANALYSIS AND PRESENTATION 
Cancer survivorship MOC 
The first component of this integrative literature review was to identify different models 
of survivorship care (Table 2). Characteristically, hospital based follow-up care is commonly 
specialist-led, with often no end point [27, 29]. Survivors may acquire an impression the 
specialist has become their primary carer, particularly if they have assessed and treated co-
morbid conditions during the treatment phase [7]. Multidisciplinary disease-specific clinics [5, 9, 
7] and survivorship clinics were most often a one-time consultation for an assessment, plan of 
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follow-up care provision and referrals to other health care providers [1, 30]. Clinics within this 
framework frequently consulted on one aspect of post treatment care, such as late effects [9]. 
Nurse-led survivorship clinics, as described, were mostly hospital based and delivered a 
number of interventions including: information; symptom management; psychosocial support; 
allied health referrals and health promotion strategies [27]. They can involve longer 
consultations and more frequent patient contact [27, 6]. PCP-led models involved a complete 
transition of all care from the hospital specialist to PCP [28, 5, 9]. This can be challenging for 
specialists who decide to transition care, as the level of knowledge and experience amongst PCPs 
can differ [5, 30]. 
 Shared care models involved more than two providers sharing care and responsibility [1, 
9]. According to Oeffinger, McCabe [7], after treatment completion, the PCP assumes 
responsibility for: maintenance of survivor health; management of any co-morbid conditions; 
ongoing physical and psychosocial concerns; and health promotion. The medical specialist 
provides a survivorship care plan and treatment summary and ongoing consultation for 
recurrence or problematic late effects if required. Both providers are to undertake monitoring, 
therefore a clear delineation of responsibility for particular screening and surveillance is 
important [5]. Landier [5] identified shared care as appropriate for low risk and even some 
moderate risk patients, however intensively treated patients (i.e. haematological cancers) require 
specialist monitoring.  
 
Nurse-led 
The two studies that evaluated nurse-led follow-up in lymphoma survivors predominately 
targeted late effects and health promotion. Gates et al. [31] studied a nurse-led component of a 
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haematology late effects survivorship multidisciplinary team, whereas John, Armes [32] reported 
on nurses replacing specialist-led follow-up, independently delivering comprehensive 
survivorship care. Both clinics assessed for supportive care needs and concerns and delivered 
health promotion and information [31, 32].  John, Armes [32] provided an annual clinic with 
nurse contact details, whereas Gates et al. [31] delivered four consultations over a six month 
period. Both studies measured different outcomes and utilised different comparative groups, 
thereby making them difficult to compare, especially as Gates et al. [31] has only published 
preliminary results. John, Armes [32] prospective comparative study of 61 patients concluded 
that patient satisfaction was equivalent in the nurse-led clinic cohort compared with the medical-
led clinic cohort and was in some cases preferred. However, the number in each group was not 
reported and it is possible patient satisfaction was related more to the decrease in wait times. It 
would likewise be difficult to attribute lifestyle changes to the clinic as patients were seen 
annually.  
 
Physician-led 
The included physician-led studies (n=4) presented comparisons of self-reported 
practices in survivorship follow-up [8] and clinician perceptions of survivorship follow-up [33-
35]. A qualitative exploratory study by Chubak et al. [33] reported the views of clinicians and 
administrators (n=40) from 10 integrated cancer centres. All respondents reported shared care 
was being practised. This was based on the assumption that all survivors have a PCP, and despite 
respondents reporting a lack of standard approaches to sharing care between clinicians. Support 
for survivorship-specific care appeared lacking, with 22% (n=9) observing it would not add to 
current care and may decrease care integration. The authors concluded that interviewing 
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respondents from sites without survivorship care would give an unbiased account. However, 
there may have been a lack of awareness related to the benefits of survivorship care. 
Dicicco-Bloom, Cunningham [8] qualitatively assessed the feasibility of a shared care 
survivorship model with 21 primary care clinicians. The overall perception was that primary 
carers are already involved in survivor follow-up, despite poor information provision from 
specialists. They perceived electronic medical records are often inaccessible. The authors further 
concluded survivorship care plan reasearch is limited. PCPs felt excluded once patients entered 
the hospital system, especially when follow-up extended well past treatment, to healthy patients 
with no recurrent cancer. This was reflected in the study by Greenfield et al. [35] who reported 
the views of clinicians (n=475) regarding long-term follow-up and found only 5% (n=14) of 
haematology cancer survivors are discharged after two years, and only 42% (n=45 lymphoma) 
and 32% (n=10 leukaemia) are discharged after five years. This finding may be explained by the 
complex and ongoing late effect sequelae in haematology patients and their expectation of long-
term specialist follow-up. Although respondent numbers were not reported, it was perceived that 
long-term specialist follow-up gave survivors false reassurance and perpetuated the illness role. 
Whereas the PCP-led model was perceived as normalising the survivors’ experience, with a 
corresponding increase in co-morbid disease management. The authors concluded by proposing a 
risk stratification process whereby low risk survivors are transitioned early to PCP and high risk 
survivors stay within the hospital model or become part of a shared care model supported by 
survivorship care plans. 
Frew et al. [34] studied survivor (n=626) and clinican (n=2302) views on different 
models of care. Respondents could choose from a number of follow-up models, but were not 
asked if they would reject a particular model. What was evident in the study by Frew et al. [34] 
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was specialist follow-up was the most experienced by survivors (84% n=528) and clinicians 
(95% n=2167). However specialists who had experienced non-specialist models of follow up 
(60% n=819) preferred this model over all others including specialist-led (87%). 
 
DISCUSSION 
Deciding upon a model of survivorship follow-up care for haematology cancer survivors 
is difficult due to the considerable variability between the types of haematological cancers, range 
of treatment regimens and long-term and late effects that impact the survivorship phase of the 
cancer continuum [17]. For haematology cancer survivors, different models have been proposed 
and utilised. However, we are unable to determine the best or the most appropriate model. This 
finding is consistent with those of Campbell et al. [36], reporting that no model was identified as 
better than any others. The reasons for these findings are that most of the articles were not 
evaluative in nature, and do not allow comparison. Patients who have only received a single 
model of care would not be able to comment on potential benefits of other models of care, 
therefore further research in understanding survivors’ perspectives of follow-up care is required. 
The transition of survivor care to the PCP requires PCP willingness. A study involving 
PCP views reported the willingness to accept exclusive care for lymphoma patients was three 
years after treatment completion [37]. This may be due to the complex nature and length of the 
treatment regimens [15] and a lack of tumour specific follow-up protocols used by 
haematologists [35]. With a lack of guidance and comprehensive information communicated 
from the haematologist [8, 35], PCPs may be reluctant to accept exclusive care of what they 
perceive as complex and ‘high risk’ patients [37]. Shared care maybe more satisfatory to 
haematologists, survivors and PCPs as it encompasses the strengths and expertise of providers 
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from more than one discipline. As a study of follow-up care providers has reported, a high 
proportion of survivors are followed up by multiple providers [38]. Therefore, it is important that 
good coordination and communication is in place to reduce the possibility of either incomplete or 
duplication of services between multiple providers. Cooper et al. [27] proposed that patients’ 
transition into survivorship phase and out to primary care through specialist nurses so that 
monitoring for recurrence, psychosocial needs and health promotion are addressed and 
communicated to survivors and health care providers. This too has implications with John, 
Armes [32] demonstrating that increased nurse workload occurred with patients utilising 
telephone contact between the scheduled clinic visits. 
Establishing survivorship care provision will require careful planning and robust 
prospective evaluations. It is important to note that coordinated survivorship care interventions 
are complex interventions [39] and can be resource intensive, requiring robust evaluations using 
patient and system outcomes. This integrative review identified the three models of care: 
physician-led, nurse-led and shared care models. Ultimately, high quality pragmatic RCTs are 
required to test the effectiveness of these models. There is an urgent need for health research 
funders to understand the need for good survivorship cancer care and fund the development and 
evaluation of the effects of various models of survivorship care. 
To the best of our knowledge, this review is the first that examines the characteristics, 
resources required and effectiveness of survivorship care models specifically for patients with 
haematological cancer. A number of limitations of this review are acknowledged. The search 
revealed only a relatively small number of articles that met the inclusion criteria. Furthermore, 
the variation of study methodology, range of measures, populations and follow-up approaches 
made it difficult to compare models of care and enabled only tentative conclusions [31, 32]. 
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Additionally, short-term follow-up or the timing of interventions may have been insufficient to 
report whether different models have impacted survivorship care. Finally, an inherent bias in 
interpretation might be due to the evaluator.  
 
CONCLUSION  
There is a paucity of effectiveness research related to haematology cancer survivors and 
specifically models of survivorship care in this cohort. Shared care models have been suggested 
as an alternative to exclusive specialist care. For shared care to work effectively ongoing 
communication channels need to be established and maintained. Nurse-led models have been 
proposed as another feasible model, where a specialist nurse intervenes directly and acts as the 
conduit between patient, hospital-based treatment team and PCP. However, more research is 
needed to define how these models should be best configured and evaluated for their 
effectiveness. For future development, a haematology-specific survivor-based needs assessment 
tool, individualised treatment summary and survivorship care plan would be integral. These 
would assist in guiding survivor-centred screening, health promotion and identification of needs 
to be monitored and managed. This approach may address many of the barriers that have been 
postulated. 
Future research will need to account for increasing cancer incidence and survival rates, 
making extensive specialist follow-up care more difficult to maintain for new patients and 
survivors. To provide quality survivorship care, new and innovative models of haematology 
survivorship follow-up are required that address the need for long-term follow-up that accounts 
for potential late treatment effects, risks of secondary cancers, development of treatment related 
co-morbid conditions and psychosocial well-being. This review revealed a lack of high quality 
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evidence suggesting the effectiveness of any single model of care. A well-designed pragmatic 
randomised controlled trial, assessing patient and system outcomes including costs, is required to 
inform clinical practice. 
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Fig. 1 Flowchart of literature search results 
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25 abstracts identified: manual 
search of preliminary literature 
2910 abstracts after duplicates removed 
239 abstracts screened 
using inclusion/exclusion 
criteria 
2671 abstracts excluded  
61 full-text articles 
assessed for eligibility 
44 articles excluded 
 
No distinction between treatment 
and survivors in follow-up 
evaluated (n=2) 
No model of care or follow-up 
evaluated (n=22) 
Perception rather than experience 
of a survivorship MOC (n=8) 
Less than 50% haematological 
cancer survivors (n=12) 
Studies included in 
qualitative synthesis 
N=17 
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Table 1 Levels of Evidence 
Level Evidence 
I Systematic review of all relevant randomised controlled trials 
II At least one well designed randomised controlled trial 
III Well-designed controlled trials without randomisation 
IV Well-designed cohort studies, case control studies, interrupted time series with a 
control group, historically controlled studies, interrupted time series without a 
control group or with case- series 
V Systematic reviews of descriptive and qualitative studies 
VI Single descriptive and qualitative studies 
VII Expert opinion from clinicians, authorities and/or reports of expert committees 
or based on physiology 
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Table 2 Existing or Proposed Models of Cancer Survivorship Care  
Setting Model  
  
Provider Model Characteristics 
Hospital  
 
 
Multidisciplinary 
survivorship clinic 
[7] 
 
 
 
 
 
 
 
 
 
 
Consultative clinic 
[27, 29] 
 
Consultative clinic 
[7] 
 
 
 
Survivorship 
follow-up clinic 
[30,1] 
 
 
 
 
 
Late effects clinic 
[9]  
 
Oncologist, network of 
consulting physicians, 
oncology or 
haematology nurse 
practitioner (NP), 
psychologist, social 
worker 
 
 
         
 
 
     
                                                          
Specialist  
 
 
Specialist 
 
 
 
 
Specialist  
 
 
 
 
 
 
Nurse and/or specialist  
 
Oncology nurse or NP 
 Can be consultative or ongoing  
 Multiple providers seen at same visit  
 Complex and resource intense 
 Co-morbid and treatment related conditions can 
be addressed  
 Can be extension of care, embedded in treatment 
team  
 Disease-specific specialist defines follow-up 
plan 
 NP follow-up who communicates with PCP to 
initiate shared care 
 Large patient cohort needed 
 
 Ongoing (rarely Oncologist takes on primary 
carer role) 
 
 One-time comprehensive visit  
 Treatment summary and survivorship care plan 
 Review of recommendations – surveillance, 
screening, health promotion 
 
 Separate from routine care  
 Holistic assessment of survivor 
 End of treatment or on maintenance therapy 
 Treatment summary, survivorship care plan and 
individualised information provision 
 Can have telephone follow-up 
 
 Haematology / Oncology treatment centres  
 
 Comprehensive, long-term follow-up to assess, 
25 
 
Nurse-led  [27, 1]  and provide primary care needs 
 ASCO surveillance recommendations used 
 Clinic and/or telephone follow-up 
Primary 
Care 
 
 
General 
survivorship clinic 
[28, 5] 
 
 
PCP-led [9] 
Nurse collaboration 
with practice specialist 
PCP (i.e. breast care 
PCP) 
 
PCP 
 Referral for services or refers to specialists 
 
 
 Full transition to PCP after treatment completion  
 Can have communication from specialist: late 
effects management and surveillance 
 Usually low risk for recurrence or late effects 
Shared 
Care 
 
Shared care  
[1, 7] 
Specialist & PCP  Oncologist for oncology related issues 
 PCP for co-morbidities, other cancer screening 
and prevention 
ASCO American Society of Clinical Oncology; NP Nurse practitioner; PCP primary care physician 
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Table 3 Methodological Characteristics of Models of Haematological Cancer Survivorship Care (n=6) 
Author  
 
Year 
 
 Country 
Study 
Design 
MOC  
 
Provider 
Disease 
 
Years Post 
Treatment 
 
Sample Size 
(Response 
Rate %) 
Resources 
Required 
Potential 
Benefits 
Potential 
Deficits 
Outcome 
Measures 
Results Level of 
Evidence 
Chubak et 
al. [33] 
 
2012 
 
USA 
Exploratory 
study 
Semi-
structured 
telephone 
interviews  
 
 
 
Shared care  10 Cancer 
Research 
Network sites 
 
Cancer types 
not identified 
 
40/48 (83%) 
Administrator
s / clinical 
leaders 
/providers in 
oncology, 
primary care 
Survivorshi
p care plan 
(SCP) - 
only 5 
responders 
identified 
use of 
 
Support 
groups  
Time and 
lack of 
specialists 
to follow-
up 
survivors 
Clearer 
evidence to 
support 
survivorshi
p care 
needed 
 
6/10 sites 
survivor 
specific 
tools not 
being used  
Perspectives 
on: survivors 
needs; 
current 
survivorship 
practices; 
barriers; 
areas for 
future 
research 
Only 2/10 sites 
had formal 
survivorship 
programs (1 
nurse-led, 1 
physician 
assistant-led) 
 
Responses for 
survivorship care 
needs: address 
fear recurrence 
35%; information 
on long-term 
effects 40%; 
nutritional and 
exercise support 
27%; 
psychosocial 
support 62.5% 
 
Overall 
uncertainty about 
best models of 
survivorship care 
 
VI 
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DiCicco-
Bloom & 
Cunningha
m [8] 
 
2013 
 
USA 
In-depth 
interviews 
on 
information 
sharing 
to/from 
specialist & 
patients 
Shared care  21 Primary 
care clinicians 
(PCC) (11 
PCP & 10 NP)  
 
Unknown 
patient types 
or 
survivorship 
period 
Electronic 
medical 
records 
access  
 
SCP 
Primary 
care 
perspective 
 
Information 
sharing 
ensures 
effective 
care 
transitions 
No 
guidelines 
or 
consensus 
for many 
cancers on 
screening, 
surveillanc
e, late 
effects (LE) 
Understand 
nature of 
interactions 
between 
primary care, 
specialist & 
patient  
Absence 
systematic 
information 
sharing among 
PCP, patient, 
specialist 
 
Some patients 
continue to see 
PCC during 
treatment 
 
Reliance on 
patients to 
provide clinical 
information from 
specialist (not 
always reliable 
for complex 
conditions / 
treatment) 
 
Academic 
hospital settings 
were worst in 
communication to 
PCC  
 
SCP effect on 
patient outcomes - 
limited evidence 
VI 
Frew et al. 
[34] 
 
2010 
Compariso
n survey on 
models of 
follow up 
Models 
presented for 
perception & 
experience: 
Cancer 
diagnosis or 
treatment not 
disclosed 
Nil 
described 
Non-
specialist 
models 
tend to 
Survey did 
not ask for 
survivor 
diagnosis & 
Perceptions 
of reasons 
for follow-
up; levels of 
Reasons for 
follow-up:  
monitoring for 
early 
IV 
28 
 
 
UK 
hospital based; 
telephone; 
non-specialist; 
group; patient 
managed; no 
follow-up 
 
Range to over 
10 years 
 
626 (21%) 
survivors/care
rs  
 
940 (32%) 
PCP 
 
804 specialists 
(including 
haematologist
s) 558 nurses 
/allied health 
(47%) 
provide 
more 
psycho-
logical 
support 
treatment 
which may 
alter model 
preference 
 
Survey did 
not ask if 
any models 
would be 
rejected so 
potential 
deficits not 
identified 
preference 
for different 
follow-up 
models; 
effect of 
individual 
experience 
on follow-up 
model 
preference 
complications; 
detecting 
recurrence; 
detecting LE, 
providing 
information & 
support (70%) 
 
Preference for 
model of follow-
up experienced: 
86% survivors 
preferred hospital 
based follow-up 
and was 
experienced most 
(84%) 
 
Clinicians had 
experience of 
more models of 
follow-up  
 
Specialists 
endorsed non-
specialist or 
patient managed 
follow-up (87%)  
PCP endorsed 
hospital based and 
patient managed 
follow-up (83%) 
Gates et al. 
[31] 
 
Quasi-
experiment
al 
Late effects 
MDT 
(haematologist
HL 
 
5 years 
Education 
package 
 
Health 
promotion  
 
SCP not 
given until 
2nd visit (at 
Primary 
outcome: 
health 
No final 
published results 
from this study 
IV 
29 
 
2012 
 
Australia 
comparison 
healthy 
cohort 
versus 
Hodgkin 
lymphoma 
(HL) 
survivors 
, transplant 
physician, 
radiation 
oncologist, 
cardiologist, 
endocrinologis
t, primary care 
liaison, 
psychologist, 
LE social 
worker, LE 
CNC) 
 
Nurse-led 
clinic for  
health 
promotion: 2 
visits + 2 
phone calls  
 
 
30 HL + 30 
healthy 
participants 
(91%) 
Screening 
tools 
(Late 
Effects 
Supportive 
Care Needs 
Screening 
Tool; The 
General 
Health 
Index; The 
Health 
Promoting 
Lifestyle 
Profile II) 
 
SCP copy 
to survivor / 
PCP 
Psychosoci
al issues 
identified 
& resources 
and support 
given 
 
Importance 
of 
surveillanc
e  
 
Survivor 
sees all 
relevant 
providers 
on same 
day 
4 months) 
 
promotion 
intervention 
from nurse to 
improve HL 
survivors 
knowledge 
and 
motivation to 
adopt health 
promoting 
behaviours 
 
Secondary 
outcomes: 
improved 
perception of 
health status; 
reduced LE 
unmet needs; 
reduced LE 
worry 
Anecdotal 
analysis shows 
appreciation of: 
SCP; screening 
assessment  
Greenfield 
et al. [35] 
 
2009 
 
UK 
E-survey 
comparison 
of clinician 
views on 
long-term 
follow-up 
PCP-led 
 
18-45 year old 
breast, 
lymphoma, 
leukaemia, or 
germ cell 
survivors 
 
> 2 years 
 
421 cancer 
clinicians 
(36% 
haematologist, 
33% 
Communica 
tion 
 
Specialist 
nurse 
support 
(91% most 
important 
resource) 
 
Risk 
stratificatio
n - low risk 
to PCPs, 
Specialists 
can focus 
on acute 
care 
 
Lower 
costs 
 
PCP: 
existing 
relationship 
with 
survivor; 
accessible; 
Potential 
loss of 
outcome 
data, LE 
information 
to 
specialists 
 
PCP: Lack 
expertise in 
survivorshi
p issues, 
increases 
survivor 
Compare 
long-term 
follow-up: 
reasons for 
follow-up; 
advantage / 
disadvantage 
of PCP-led 
follow-up; 
current 
practice; 
resources 
and support 
required 
Specialists rated 
clinical reasons 
for follow-up 
higher  
Nurses and PCP 
rated both clinical 
& supportive 
reasons higher 
 
Reasons for 
follow-up: PCP 
rated recurrence 
(96%) 
Specialists rated 
IV 
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oncologist, 
18% surgeon, 
10% nurse, 
2% other)  
 
54 PCP 
 
 
high risk 
hospital 
follow-up 
 
SCP & 
Treatment 
summary 
(TS)  
convenient; 
knowledge 
of local 
support; 
expertise in 
chronic 
health 
 
anxiety, 
time  
issues 
 
No tumour 
specific 
follow-up 
guidelines 
 
 
LE (76%) 
recurrence (71%) 
 
Haematologist 
use of follow-up 
protocol for 
leukaemia and 
lymphoma 19%  
 
Discharge to PCP: 
5% at 2 years  
42-32% by 5 
years  
John & 
Armes [32] 
 
2013 
 
UK 
Prospective 
comparison 
specialist-
led versus 
nurse-led 
Survivorship 
follow-up 
clinic 
 
Nurse-led 
(replaces 
specialist 
follow-up) 
Lymphoma 
 
3 years 
 
50 notes 
audited (25 
per group) 
 
120 survivors 
(60 per group) 
assessed wait 
time 
 
 61 (82%) 
survivors 
assessed 
patient 
satisfaction 
(unclear split 
medical-led 
versus nurse-
led) 
2 CNS 
 
Information 
prescription 
Longer 
consultatio
ns 
 
Written 
information 
provision 
 
Holistic 
needs 
assessment 
Monitoring 
for late 
effects  
Health 
promotion 
 
Post 
treatment 
contact 
Annual 
clinic visit  
 
Preferred 
clinic not 
assessed 
 
 
 
Documenta 
tion 
 
Wait time 
 
Patient 
satisfaction 
Documentation 
improved – 50% 
of psychological 
& sexual issues 
still not recorded  
 
Wait times 
reduced from 
average 65 mins 
(specialist) to 10 
mins (Nurse) 
 
Nurse-led was 
equal to 
specialist-led 
clinic and 
preferred in some 
areas  
 
Nursing telephone 
workload 
increased  
IV 
31 
 
CNC Cancer Nurse Consultant; CNS Cancer Nurse Specialist; HL Hodgkin Lymphoma ; LE Late effects; MDT multi-disciplinary team; MM multiple 
myeloma; NHL Non-Hodgkin Lymphoma; NP Nurse practitioner; PCP primary care provider; SCP survivorship care plan; TS treatment summary 
 
